Pod Insights Short Wave Could this vaccine trial mean a future without HIV? About this episode Early last year, a hundred researchers, clinicians and other experts on HIV discussed the development of an innovative vaccine that could prevent the disease. But just as the meeting was about to wrap up, the mood darkened. A new executive order signed by President Trump on Inauguration day had frozen all foreign aid, pending a review. Soon, DOGE would begin its decimation of USAID https://www.npr.org/sections/goats-and-soda/2025/07/01/g-s1-75222/usaid-trump-humanitarian-rubio-musk — and with it, this vaccine trial. That is – until the South African researchers came up with a new plan.
Read more of freelance science reporter Ari Daniel’s story here https://www.npr.org/2026/01/17/g-s1-106007/hiv-vaccine-trial-south-africa.
This story was supported by a grant from the Pulitzer Center.
Interested in more on the future of science? Email us your question at shortwave@npr.org mailto:shortwave@npr.org.
Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave http://plus.npr.org/shortwave.
See pcm.adswizz.com https://pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy https://www.npr.org/about-npr/179878450/privacy-policy
Transcript 2,138 words · 10 speakers
0:00 Speaker 00 This message comes from Google Workspace with Gemini. One subscription that does it all. Personalized AI and premium business versions of Gmail, Google Docs, Drive and more. Try it free for 14 days at goo.gle/workspacewithgemini.
0:19 Speaker 01 You're listening to Short Wave from NPR.
0:25 Speaker 02 Hey, Short Wavers. Science correspondent Nate Roth here, filling in for Emily and Regina. Today, we're going to talk about a global disease that's long hammered Sub-Saharan Africa particularly hard: HIV.
0:36 Speaker 03 Specifically, we're going to talk about a vaccine to fight HIV.
0:41 Speaker 02 So Ari Daniel, for those who don't recognize your dulcet tones, is a freelance science reporter. And Ari, I hear there's a pretty remarkable backstory to this vaccine we're going to talk about.
0:51 Speaker 03 That is correct.
0:52 Speaker 02 OK, so where do you want to start? All right.
0:56 Speaker 03 Right here, Nate. Inside a lab at the National Institute for Communicable Diseases in Johannesburg, South Africa.
1:03 Speaker 02 Cool.
1:03 Speaker 03 It's arrayed with, if you can picture it, half a dozen large, green and white freezers.
1:09 Speaker 04 These are the freezers that contain the samples that are the basis of everything we do in the lab.
1:14 Speaker 03 This is Penny Moore. She's a virologist at the University of Ibadrstrand.
1:19 Speaker 04 Our freezers are named after the seven dwarves.
1:23 Speaker 02 I've always felt a strong affinity for sleepy.
1:26 Speaker 04 So you have happy and grumpy, and every freezer in the lab is named after somebody.
1:33 Speaker 03 So Penny cracks open the lid of Bashful and pulls out a tower of frosty tubes.
1:41 Speaker 04 It's heavy and hard for me to lift. So this is blood and cells.
1:47 Speaker 03 These, Nate, are all the samples that have been donated to Penny and her team over and over again for two decades by the same group of 117 South African women.
1:58 Speaker 02 Whoa, so just to be clear, Ari, you mean they collected blood from the same group of women for 20 years?
2:03 Speaker 03 That's right.
2:04 Speaker 02 Who are these women?
2:05 Speaker 05 They live in the communities that are most ravaged by HIV. And they donate their samples because they hope to see an end to an epidemic that is really, really real for them.
2:15 Speaker 03 These samples have helped Penny and her team piece together a detailed portrait of the virus over the years. How it infects, how it hides, and how much it changes across different parts of the world and even within a single individual. This research has also helped fight other diseases, including COVID-19, RSV, and cancer.
2:37 Speaker 05 The amount we have learned from these freezes, it's just astonishing.
2:42 Speaker 03 And yet, despite all that, Nate, Penny actually spent much of last year worrying that it might all amount to nothing.
2:49 Speaker 02 Why?
2:50 Speaker 03 Well, because just when she and her colleagues were on the brink of an innovative HIV vaccine trial across Africa, the bottom dropped out. Lynda Gail Becker directs the Desmond Tutu Health Foundation in South Africa.
3:03 Speaker 06 In many ways, we've kind of had our legs cut off, even as we're beginning to run the sprint.
3:10 Speaker 02 That's a vivid description.
3:11 Speaker 03 But the team, they steeled their resolve. They knew the science was sound and the need was urgent. They insisted on finding a way forward.
3:21 Speaker 02 Wow, OK. So today on the show, the Pan-Africa HIV vaccine trial that was almost over before it even started. You're listening to Short Wave, the science podcast from NPR.
3:42 Speaker 01 Stay tuned for the following announcements and messages from our sponsors. This message comes from ProLon. With their five-day fasting-mimicking diet, a clinically-developed nutrition program with the goal of promoting fat loss while protecting lean body mass. Learn more at prolonlife.com/NPR.
4:00 Speaker 01 This message comes from Edward Jones, where they believe rich isn't about having life all figured out. It's opening yourself to all the possibilities. That's why your dedicated financial advisor provides long-term planning built around you, meeting you where you are and helping you get closer to where you want to be. So no matter where you're starting from or wherever life takes you, you can move forward with confidence. The key to being rich is knowing what counts. Let's find your rich together. Edward Jones. Member SIPC.
4:34 Speaker 00 This message comes from Google Workspace with Gemini. One subscription that does it all. Personalized AI and premium business versions of Gmail, Google Docs, Drive, and more. Try it free for 14 days at goo.gle/workspacewithgemini.
4:52 Speaker 02 Okay, we're back. Ari, where do we pick up this story?
4:55 Speaker 03 Well, to explain what was going on, we have to kind of rewind to about a year ago in early 2025 to a meeting that was held in Zanzibar.
5:05 Speaker 05 The famous Zanzibar trip.
5:07 Speaker 02 Zanzibar, Zanzibar, Zanzibar is very far. You can't get there in a car. It's too far to Zanzibar. I've actually been to Zanzibar, Ari, and it is stunningly beautiful.
5:17 Speaker 03 Have you?
5:17 Speaker 02 I have, yes.
5:18 Speaker 03 Well, so you know it's a tropical archipelago off the east coast of Africa. So, as you so kindly pointed out with your lyrics, very far. And when Penny was there with her hundred or so colleagues for that meeting, she says it was just crazy hot.
5:35 Speaker 05 One of those places where you just consider standing up and you break out in a sweat.
5:40 Speaker 03 The gathering took place in a hotel perched on the edge of a brilliant blue ocean. There were researchers and clinicians from across Africa. And then there were the international scientific advisors.
5:52 Speaker 05 They gruelled us to within an inch of our lives. To make sure that we were doing the very best cutting edge science we could do with the amount of money we had.
6:00 Speaker 02 What money are we talking about here? Are like, how much?
6:03 Speaker 03 Penny and her colleagues had gotten a $45 million grant from the United States Agency for International Development, or USAID, to create a state of the art vaccine to prevent HIV.
6:15 Speaker 02 Oh, wow.
6:15 Speaker 03 The goal was to get teams across the continent to collaborate on developing something that would work in different African communities.
6:23 Speaker 02 OK, so a vaccine that would work across different parts of the continent because HIV, as you pointed out, the virus is different from country to country.
6:31 Speaker 03 Exactly, and within a country and even between individuals. So at this meeting in Zanzibar, there was a real feeling of momentum. Nunu Mkize is a colleague of Penny's and a senior medical scientist.
6:45 Speaker 07 The excitement was through the roof at the beginning of something.
6:48 Speaker 03 But just as that meeting was about to wrap up, Penny says the mood darkened.
6:54 Speaker 05 From the number of Americans particularly checking their phones all of a sudden and talking to one another in little huddles.
7:01 Speaker 02 I got a feeling I know where this is going.
7:04 Speaker 03 Yep. As you may recall, Nate, President Trump, who'd just been inaugurated at that point, had signed an executive order freezing most foreign aid.
7:12 Speaker 02 Wow, and I'm assuming that included this grant.
7:15 Speaker 03 Yeah.
7:15 Speaker 05 I remember at the end of the meeting, USAID colleagues saying to me, I'm not sure if I'll see you again. I completely underestimated how much it would gut the program.
7:25 Speaker 03 But Penny and her colleagues soon found out. After returning to Johannesburg, she says the official stop work orders arrived from Washington just weeks before the trial was to begin. Everything came to a sudden halt. All the money was gone. And remember Lynda Gail Becker from the top of the episode?
7:43 Speaker 02 Yeah, she was the one that said that their legs had been cut off before they started sprinting, right?
7:47 Speaker 03 That's the one. She says when the funding collapsed, she cycled through the stages of grief.
7:52 Speaker 02 I bet. I mean, after decades of work by her and her colleagues, collecting blood samples and all that work.
7:58 Speaker 06 There's disbelief in the first instance. Then there is emotion that basically is angry because we'd worked damn hard, we'd won this grant, and we were doing what we had said we would do.
8:11 Speaker 03 But soon, this team of researchers decided that they needed to find a different way forward.
8:17 Speaker 06 This matters too much to not finish the work. We brought out the begging bowl.
8:22 Speaker 03 A period of frantic grant writing began, and finally, they got funding from the South African Medical Research Council and the Gates Foundation.
8:31 Speaker 02 Okay, well, that's good. So were they able to get another $45 million?
8:35 Speaker 03 No, they couldn't raise that much, but they did get about 2.2 million.
8:39 Speaker 02 Okay, that's still money, but a lot less money. Did they have to scale back their ambitions then?
8:46 Speaker 03 Of course. The new grant was focused inside South Africa only, and that meant that they had to sacrifice studying how the vaccine might work against different versions of the virus within different African populations. Here's Penny Moore again.
9:03 Speaker 05 It's a bare bones version. We will still get the answer, but it's going to cost us time, years, which is not trivial, because people are getting infected with this virus constantly.
9:13 Speaker 03 Despite having to reduce the scope of the grant, though, Penny told me that HIV vaccine research is farther along than it's ever been.
9:25 Speaker 02 Ooh, I hear a door. Are we going back into that noisy seven-door freezer room?
9:30 Speaker 03 You know it. It contains all those samples that those 117 women have donated over the years.
9:37 Speaker 05 These samples have taught us everything we know about HIV.
9:41 Speaker 03 Including why the virus is so skilled at evading our bodies defenses. But remarkably, in the blood of a few of these women, something pretty special surfaced after they became infected with HIV. Penny tells me in her office, it's something called a broadly neutralizing antibody.
9:59 Speaker 05 A broadly neutralizing antibody could stop my virus and could stop your virus and could stop the HIV virus from any other person.
10:05 Speaker 03 Oh, wow.
10:06 Speaker 05 And in many cases, up to 90% of global viruses could be stopped by one antibody.
10:11 Speaker 02 Okay, so this is like a super antibody. Does it wear a cape?
10:16 Speaker 03 Not exactly, but you're on the right track, Nate, because compared to regular antibodies, these guys are weird looking.
10:23 Speaker 02 Okay.
10:23 Speaker 03 Some have really long arms, some have super short arms, and this oddness gives them a way of dealing with HIV's defenses. But when these rare antibodies appear naturally in someone's body, they usually emerge too late to help that person living with HIV.
10:41 Speaker 02 Okay, so they usually emerge too late, but is there a way for the researchers to somehow like coax the human immune system, let's say, to like produce these antibodies before they become infected with HIV so they have some defenses?
10:53 Speaker 03 Bingo. That is the whole point of this vaccine trial, to figure out how to do that more easily.
11:00 Speaker 02 Okay, cool. So has it started? Like, is the new vaccine trial underway?
11:04 Speaker 03 Finally, after nearly a year of delays. I head to the outskirts of Cape Town, where a large brick building rises above Felipe Village, this impoverished township where HIV is rampant. And a few levels up, I spot Amelia Ntheki, the community liaison officer for the vaccine trials.
11:26 Speaker 08 This is a great opportunity for South Africa to prove that we can do things in South Africa, for South Africa, with South African financing.
11:33 Speaker 03 Amelia makes her way to a room where 20 or so young women are gathered to hear about participating in the trial.
11:41 Speaker 08 HIV vaccine. Now, who are these 20-some young women, Ari?
11:46 Speaker 03 Well, all these women are from the community, Nate, including Nandip Hamongo. She's 25 years old, and she tells me that her community struggles with rape, sex traded for favors, unplanned pregnancies.
11:59 Speaker 09 Most of us are scared of getting HIV.
12:02 Speaker 03 Which is why she'd happily be involved in the research.
12:07 Speaker 09 I'm over the moon, man. I'm over the moon. Yes.
12:10 Speaker 02 Oh, that's awesome.
12:11 Speaker 03 Because she's proud to be making a difference.
12:14 Speaker 09 Yes, a big one, a big difference.
12:17 Speaker 03 I ask, if this team of researchers is able to find a vaccine, what would a world without HIV be like?
12:25 Speaker 09 Living free. Yeah.
12:30 Speaker 02 Do we have a sense, Ari, of when the first shots of this new vaccine will start going into people's arms?
12:35 Speaker 03 It already started, Nate, in January, and it's going to continue for some months.
12:40 Speaker 02 Wow, I'm excited to hear how this goes. Thank you so much, Ari, for bringing us this story.
12:46 Speaker 03 Of course, Nate. Thanks for having me.
12:49 Speaker 02 Ari Daniel is a freelance science reporter. In short waivers, if you liked this episode, follow us on the NPR app or wherever you listen to podcasts. Also, check out our episodes on When Your Brain Is Fully Developed and Cratum. Reporting for this story was supported by a grant from the Pulitzer Center. Thank you, Pulitzer Center. The Gates Foundation is a financial supporter of NPR. Thanks for listening to Short Wave from NPR. See you next time.
13:25 Speaker 01 Stay tuned for the following announcements and messages from our sponsors.
Previous Why do we kiss? It's an evolutionary conundrum Next Tea time... with an ape? Page updated October 31, 2026 · transcript and summary are machine-generated